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MinireviewAnimal Models of PD:
Pieces of the Same Puzzle?
lated studies led to the discovery that the motor symp-
toms of PD were due to nigrostriatal DA depletion and
the eventual use of DA replacement as the mainstay of
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therapy for PD. Although DA depleting agents produce2 Department of Neurology
parkinsonian signs, their effects are transient, and they3 Department of Neuroscience
do not elicit DA neuronal death.4 Department of Pathology
A popular model using intraparenchymal neurochemi-Johns Hopkins University School of Medicine
cal lesioning of the striatum, SNc, or nigrostriatal path-Baltimore, Maryland 21287
way by 6-hydroxydopamine (6-OHDA) in a variety of
species reliably destroys DA neurons and produces par-
kinsonism (Table 1) PD (Beal, 2001). The 6-OHDA modelParkinson’s disease (PD) is a common neurodegener-
has been quite predictive of symptomatic and cell re-ative disorder with no known cure. The etiology of
placement therapies for PD and is of value in investigat-PD is likely due, in part, to combinations of genetic
ing regenerative therapies. However, it is an imperfectsusceptibilities and environmental factors. In rare fa-
model, in that it is acute and does not replicate manymilial cases, PD is due to genetic mutations. A number
of the features of PD.of new genetic and toxin models of PD and advances
The discovery that the accidental use of the neuro-in older models are yielding important new information
toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineabout the pathogenesis of PD. This has prompted us
(MPTP) in drug addicts produces parkinsonism in hu-to critically review the current animal models for PD
mans has provided many important insights into theand discuss how these models may yield fresh insights
pathogenesis of PD (Beal, 2001; Dunnett and Bjorklund,into the pathogenesis of PD, as well as new therapeutic
1999). Thus, it is more than merely just a DA depletionopportunities.
model. Systemic MPTP intoxication in a variety of spe-
cies satisfies most of the requirements for an ideal par-An ideal animal model would recapitulate most, if not all,
kinsonian model (Table 1), with the exception that it isthe features of sporadic PD (Table 1). The degenerative
an acute, nonprogressive insult. However, administra-process of PD usually begins in late adulthood. It is
tion of MPTP in smaller doses over a prolonged periodrelentlessly progressive and initially causes a preferen-
may provide progressive, permanent depletion of nigro-tial loss of dopamine (DA) neurons within the substantia
striatal DA. In primates, MPTP intoxication replicates allnigra pars compacta (SNc), leading to motoric dysfunc-
the clinical signs of sporadic PD and leads to neuronaltion (slowness of movement, rigidity, rest tremor, and
nonfibrillar inclusions that contain -syn (Beal, 2001).postural instability). In many cases of PD, cognitive dis-
DA neuron selectivity of MPTP-induced neurotoxicityturbances and degenerative changes in non-DA neurons
stems from the conversion of MPTP to 1-methyl-4-phe-are prominent features. During the initial stages of PD,
nyl pyridium (MPP) by monoamine oxidase B and fromexcellent symptomatic relief can be achieved with DA
avid affinity of MPP for the dopamine transporter. Oncereplacement therapy. However, as the disease prog-
inside DA neurons, MPP is actively concentrated withinresses, these medications and other adjunctive thera-
the mitochondria where it binds to and inhibits complexpies become less effective and patients eventually be-
1 of the mitochondrial electron transport chain, thereby
come disabled. In addition to the loss of DA neurons, a
leading to oxidative stress and neuronal cell death.
key determinant that differentiates this disorder under
These observations spawned the discovery of mito-
most circumstances from other neurodegenerative dis- chondrial dysfunction and reduction of complex 1 activ-
eases that also exhibit nigrostriatal degeneration is the ity in sporadic PD. Use of MPTP animal models, particu-
presence of Lewy bodies (LBs) and Lewy neurites (LNs). larly primate models, led to improved symptomatic
LBs and LNs are eosinophilic cytoplasmic protein- surgical and medical therapies in PD. Despite the poten-
aceous inclusions that contain -synuclein (-syn), ubi- tial strength of this model, to date, no neuroprotective
quitin-proteasomal proteins, synphilin, neurofilaments, or neuroregenerative pathway or agent identified in the
microtubule-associated proteins, synaptic vesicle- MPTP model has been shown to be efficacious in PD
associated proteins, and markers of oxidative stress. patients, except for fetal DA neuron transplants. Per-
Ultrastructurally, LBs are composed of 10–16 nm fila- haps the lack of predictive value relates to the acute
ments that radiate from the central core, and -syn is nature of the MPTP intoxication model, or we do not fully
the major component of these filaments. Another key understand the complexity of neuronal degeneration in
feature of PD is selective loss or deficits in the activity PD. However, the verdict on the predictability of the
of mitochondrial complex 1 and increased indices of MPTP model for neuroprotective and regenerative ther-
oxidative stress. apies is still unsettled. In particular, recent use of geneti-
Intoxication Models of PD cally engineered mice and biochemical reagents have
Early animal models of PD relied on the depletion of DA revealed important new information about the molecular
by pharmacologic agents such as reserpine (Table 1) mechanisms affecting the degeneration of DA neurons,
(see Beal, 2001, and references therein). These and re- including the role of reactive oxygen species, excitotox-
icity, caspase-dependent and -independent forms of
cell death, and the role of microglia (Figure 1). Further-5 Correspondence: tdawson@jhmi.edu
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Table 1. Key Features of Current Animal Models of PD
Progressive
Progressive Age-Dependent Mitochondrial
Age-Dependent Degeneration of Motor L-DOPA Complex 1 LB-Like
Model Loss of DA Neurons Non-DA Neurons Deficits Responsive Deficiency Inclusions
Intoxication models
Reserpine      
6-OHDA  (acute  (acute)   ? 
MPTP  (acute)     nonfibrillar
-syn inclusions
Rotenone      









PDGF-Hu WT -syn ↓TH ?  ND ND atypical -syn
inclusions
Thy1-Hu WT or A53T    ND ND nonfibrillar
-syn -syn inclusions
TH-Hu A30P/A53T ↓DA   ND ND nonfibrillar
-syn -syn inclusions
Mouse PrP-Hu A53T    ND ND 
-syn
Rat:
AAV-Hu WT or A53T     ND nonfibrillar
-syn -syn inclusions
Not all familial or intoxication models are listed. Transgenic -syn models that do not have significant pathology are not listed (see Lee and
Price, 2001, and references therein). Only the pan-neuronal promoter -syn transgenic flies are reported (see Feany and Bender, 2000).
Abbreviations: ND, not determined.
more, advances in regenerative therapies have arisen structural similarity to MPP. Systemic administration
from studies of MPTP intoxication, and many of these of paraquat causes DA neuronal loss and striatal dopa-
discoveries are currently in various stages of therapeutic minergic denervation and aggregation of -syn in ro-
development (Beal, 2001; Dunnett and Bjorklund, 1999). dents (Manning-Bog et al., 2002; Thiruchelvam et al.,
Several epidemiological studies suggest that pesti- 2000). The agricultural use of paraquat often parallels
cides and other environmental toxins may be involved the use of the fungicide manganese ethylenebisdithio-
in the pathogenesis of PD (Table 1) (Beal, 2001). The carbamate (maneb). Interestingly, in mice, systemic ad-
common herbicide paraquat (1,1-dimethyl-4,4-bipyri- ministration of maneb potentiates the DA toxicity of
dinium) is a putative risk factor for PD based on its paraquat (Thiruchelvam et al., 2000). The combined use
of paraquat and maneb as an animal model for PD is
still in the early stages, but it holds particular promise
as an important model due to the potential role of envi-
ronmental toxins in the etiology of sporadic PD.
Rotenone, another agricultural toxin that is used as
an insecticide and fish poison, produces parkinsonism
in rats when administered intravenously (Table 1) (Betar-
bet et al., 2000). Rotenone is a mitochondrial complex
1 inhibitor, but it differs from MPTP in that rotenone acts
uniformly throughout the brain; thus, DA neurons are
uniquely sensitive to mitochondrial complex 1 inhibition.
This model is quite remarkable as the rats develop pro-
gressive degeneration of nigrostriatal DA neurons and
inclusions that stain with antibodies against ubiquitin
and -syn. These inclusions contain a dense core sur-
rounded by fibrils, similar to LBs. Thus, derangements
in mitochondrial complex 1 appear to be directly linked
with alterations in -syn. Furthermore, the rats have
clinical signs reminiscent of PD including bradykinesia,
postural instability, unsteady gait, and tremor that re-
spond to the dopamine agonist apomorphine. AlthoughFigure 1. PD Models–Pieces of the Same Puzzle
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this model satisfies most of the criteria for an excellent ments in striatal tyrosine hydroxylase (TH) immunoreac-
tivity or DA levels (Lee and Price, 2001; Masliah et al.,model of PD, its utility may be limited since there is a
high mortality rate, and less then 50% of surviving rats 2000; Richfield et al., 2002). Overall, these -syn trans-
genic mice represent powerful tools to investigate thetreated with rotenone develop consistent lesions.
Genetic Models of PD toxicity of -syn in vivo and factors that modulate in
vivo aggregation of -syn.Although the majority of PD is sporadic, a small percent-
age of PD is familial. Eight loci and mutations in -syn In contrast to the studies in flies, results from trans-
genic mice indicate that -syn aggregation is mechanis-(A53T and A30P) and parkin are implicated in the patho-
genesis of familial PD (see Lansbury and Brice, 2002, tically associated with neuronal dysfunction/degeneration
(Figure 1). For instance, studies in the platelet-derivedand references therein) Mutations in ubiquitin C-ter-
minal-hydrolase-L1 (UCH-L1) may also play a role in growth factor- (PDGF) human WT -syn mice suggest
that -synuclein (-syn) inhibits -syn aggregation, pre-familial PD. The discovery of familial PD-associated mu-
tations provides the opportunity to develop genetic vents loss of striatal TH, and improves Rota-rod per-
formance. Thus, -syn might function as an anti-park-models that may provide novel insights into the patho-
genesis of PD and additional models to test therapeu- insonian factor (Hashimoto et al., 2001). Moreover,
-amyloid peptides may contribute to the developmenttics. The importance of UCH-L1 in neuronal function is
indicated by a naturally occurring deletion of the uch- of LB disease as human -amyloid expression in these
mice converts nonfibrillar -syn inclusions to fibrillarl1 gene in gracile axonal dystrophy (gad) mice that leads
to degeneration of sensory axons (see Lee and Price, inclusions (Masliah et al., 2001). These biochemical
changes are associated with increased loss of DA mark-2001). No animal models of parkin mutations have been
described. A number of animal models of synucleinopa- ers in APP/-syn double transgenic mice. Expression
of human WT or A53T -syn using the Thy-1 promoterthy-induced neurodegeneration have been reported
(see Lee and Price, 2001, and references therein). also results in -syn pathology in transgenic mice with
significant degeneration of neuromuscular junctions andIn Drosophila, when human wild-type (WT) and mutant
(A53T or A30P) -syn is expressed in neurons, there is axonal degeneration (van der Putten et al., 2000).
Mice expressing human A53T mutant -syn, but nota remarkably selective age-dependent loss of subsets
of DA neurons. The loss of DA neurons is associated WT or the A30P mutant, under the control of the mouse
prion protein promoter (PrP) develop an adult-onsetwith progressive motoric dysfunction that responds to
DA replacement therapy. Moreover, the loss of DA neu- neurodegenerative disease with progressive motoric
dysfunction leading to death (Giasson et al., 2002; Leerons is associated with the presence of LB-like, filamen-
tous intracytoplasmic inclusions that contain -syn et al., 2002). Thus, A53T mutant human -syn appears to
have significantly enhanced in vivo toxicity. Neurological(Feany and Bender, 2000). Thus, the Drosophila model
is an outstanding model that recapitulates most of the dysfunction in the mouse PrP human A53T -syn trans-
genic mice is also associated with age-dependent intra-phenotypic and pathologic features of PD. The Drosoph-
ila model is a powerful and inexpensive tool that can be cytoplasmic neuronal accumulation of -syn and patho-
logical neuronal accumulations of ubiquitin (Giasson etused to rapidly screen for pharmacologic and genetic
interventions that may modify dopaminergic neuronal al., 2002; Lee et al., 2002). In affected mouse PrP human
A53T -syn transgenic mice, -syn accumulates in theinclusions and death. Indeed, overexpression of the mo-
lecular chaperone Hsp70 prevents DA neuron loss, and detergent-insoluble fractions (Giasson et al., 2002; Lee
et al., 2002). Significantly, lower molecular mass -syninterference with endogenous chaperone activity accel-
erates -syn toxicity (Auluck et al., 2002). Hsp70 pro- and higher molecular mass aggregates of -syn selec-
tively accumulate in the detergent-insoluble fractiontected DA neurons without influencing the formation of
inclusions, suggesting that LBs may play little if any (Lee et al., 2002). Lower molecular mass -syn and
higher molecular mass aggregates of -syn only accu-role in the degeneration of DA neurons. In a Drosophila
model of Huntington’s disease, histone deacetylase in- mulate in areas of the brain undergoing active neurode-
generation, suggesting that proteolytic processing andhibitors ameliorate neurotoxicity; thus, candidate thera-
peutic compounds can be screened in Drosophila (Stef- aggregation of -syn contributes to the neuropathology
(Lee et al., 2002). The mouse PrP human A53T -synfan et al., 2001). It is without doubt that the Drosophila
model will teach us much about the pathogenesis of transgenic mice are distinct in many aspects from the
other models. For instance, the pathology is more exten--syn-induced neurodegeneration in flies. However, the
challenge will be to verify potential neuroprotective sive, animals die, and unlike other studies, the -syn
inclusions contain 10–16 nm wide fibrils similar to humanagents and genetic modifiers in human PD.
A number of transgenic mice models overexpressing LBs (Giasson et al., 2002). Furthermore, neuropathologi-
cal studies on individuals with the A53T -syn mutationhuman -syn have been developed (Table 1) (Lee and
Price, 2001). While none of the transgenic -syn mice do not develop classical PD but instead exhibit exten-
sive-syn aggregates, especially in neuronal processes,accurately model PD, a number of these models exhibit
significant synucleinopathy-induced neurodegenera- similar to the observations in the mouse PrP human
A53T -syn transgenic mice (Goedert, 2001).tion, thus modeling characteristics of human -syn pa-
thology. -Syn pathology is emerging as a major patho- Overall, the results from the various -syn transgenic
mice studies indicate that formation of toxic -syn ag-genic component of a large spectrum of diverse and
related neurodegenerative diseases, designated as sy- gregates are associated with, and may be required for,
significant neurodegeneration. It is not clear why nonenucleinopathies (see Goedert, 2001, and references
therein). Only two of the models have alterations in the of the -syn transgenic models have significant abnor-
malities in DA neurons, particularly in light of the dra-dopaminergic system as manifested by modest decre-
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matic pathologic changes in Drosophila DA neurons and worth studying in humans, as the pathogenic mecha-
DA-dependent-syn toxicity in human neuronal cultures nisms may not be fully interactive. Ultimately, an ideal
(Xu et al., 2002). It is conceivable that rodent DA neurons model would exhibit all the clinical and pathologic fea-
are particularly resistant to -syn toxicity, perhaps from tures of PD, but this may be a difficult challenge as
the relative levels of -syn versus -syn, -synuclein, new insights and unforeseen pathogenic mechanisms
and/or other intrinsic protective factors. Potentially, if of neurodegeneration are bound to arise as additional
sufficient levels of -syn expression are achieved in PD-linked genes are identified, requiring refinement of
DA neurons via transgenic approaches, a model of existing models and the generation of new models.
-synucleinopathy-induced PD should be possible.
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At present, one could envisage investigating molecu-
lar mechanisms of pathogenesis in all models with the
Drosophila and MPTP models being at the forefront of
in vivo screening of therapeutic compounds. Positive
hits in the Drosophila model could be tested in -syn
transgenic mice and the MPTP model. Positive hits in
the MPTP model could be tested in -syn transgenic
mice and Drosophila. Convergence of pathogenic mech-
anisms and therapies might be particularly attractive to
test in humans. Although oxidative stress and mitochon-
drial complex 1 dysfunction promotes -syn pathology,
targets identified in either the -syn transgenic or MPTP
models that don’t work in the other model may still be
